Decipher Labs Ltd
Incorporated in 1986, Decipher Labs Ltd deals in trading and manufacturing of Pharmaceutical drugs and provides services and key solutions in Information Technology.
- Market Cap ₹ 11.4 Cr.
- Current Price ₹ 11.3
- High / Low ₹ 24.6 / 9.61
- Stock P/E
- Book Value ₹ 8.41
- Dividend Yield 0.00 %
- ROCE -4.98 %
- ROE -5.05 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 189 to 98.8 days.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -9.75% over past five years.
- Promoter holding is low: 16.4%
- Company has a low return on equity of -2.62% over last 3 years.
- Promoter holding has decreased over last 3 years: -17.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.10 | 0.22 | 0.38 | 1.02 | 6.78 | 1.42 | 0.98 | 0.99 | 0.81 | 3.53 | 0.85 | |
0.38 | 0.29 | 0.80 | 0.56 | 0.95 | 6.41 | 1.26 | 0.96 | 0.63 | 1.11 | 3.51 | 1.29 | |
Operating Profit | -0.33 | -0.19 | -0.58 | -0.18 | 0.07 | 0.37 | 0.16 | 0.02 | 0.36 | -0.30 | 0.02 | -0.44 |
OPM % | -660.00% | -190.00% | -263.64% | -47.37% | 6.86% | 5.46% | 11.27% | 2.04% | 36.36% | -37.04% | 0.57% | -51.76% |
-0.26 | -3.26 | -0.61 | 0.00 | 0.11 | 0.01 | 0.01 | 0.14 | 0.05 | -2.28 | 0.02 | 0.02 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.21 | 0.23 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.06 | 0.01 | 0.02 |
Profit before tax | -0.80 | -3.68 | -1.28 | -0.18 | 0.18 | 0.38 | 0.17 | 0.10 | 0.36 | -2.64 | 0.03 | -0.44 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.76% | 0.00% | 0.00% |
-0.80 | -3.68 | -1.28 | -0.18 | 0.18 | 0.38 | 0.17 | 0.10 | 0.36 | -2.62 | 0.02 | -0.44 | |
EPS in Rs | -1.00 | -4.60 | -1.60 | -0.22 | 0.22 | 0.48 | 0.17 | 0.10 | 0.36 | -2.59 | 0.02 | -0.44 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 24% |
5 Years: | -10% |
3 Years: | -5% |
TTM: | -76% |
Compounded Profit Growth | |
---|---|
10 Years: | -4% |
5 Years: | % |
3 Years: | % |
TTM: | -2300% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | -13% |
3 Years: | -39% |
1 Year: | -33% |
Return on Equity | |
---|---|
10 Years: | -1% |
5 Years: | -1% |
3 Years: | -3% |
Last Year: | -5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
Reserves | -0.92 | -4.60 | -5.88 | -6.06 | -5.88 | -5.50 | 0.97 | 1.06 | 1.42 | -1.20 | -1.17 | -1.61 |
0.05 | 0.00 | 0.00 | 0.05 | 0.13 | 0.14 | 0.23 | 0.14 | 0.00 | 0.00 | 0.00 | 0.24 | |
0.80 | 0.45 | 0.49 | 0.59 | 0.71 | 3.20 | 0.35 | 0.10 | 0.08 | 0.09 | 3.83 | 0.45 | |
Total Liabilities | 7.93 | 3.85 | 2.61 | 2.58 | 2.96 | 5.84 | 11.65 | 11.40 | 11.60 | 8.99 | 12.76 | 9.18 |
4.06 | 0.86 | 0.00 | 0.00 | 0.00 | 0.01 | 0.11 | 0.26 | 0.33 | 0.12 | 0.10 | 0.14 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 8.41 | 8.41 | 8.66 | 8.66 | 8.66 | 8.66 |
3.87 | 2.99 | 2.61 | 2.58 | 2.96 | 5.78 | 3.13 | 2.73 | 2.61 | 0.21 | 4.00 | 0.38 | |
Total Assets | 7.93 | 3.85 | 2.61 | 2.58 | 2.96 | 5.84 | 11.65 | 11.40 | 11.60 | 8.99 | 12.76 | 9.18 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.10 | -0.25 | -0.02 | -0.10 | 0.04 | -0.01 | 0.27 | 0.55 | -0.08 | -0.03 | 0.07 | |
0.00 | 0.00 | 0.16 | 0.00 | 0.00 | -0.05 | -0.07 | -0.19 | -0.38 | 0.09 | 0.00 | -0.05 | |
0.00 | 0.00 | 0.00 | 0.05 | 0.09 | 0.01 | 0.09 | -0.09 | -0.14 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | 0.00 | 0.10 | -0.09 | 0.03 | -0.01 | -0.01 | 0.01 | -0.01 | 0.03 | 0.01 | -0.03 | 0.03 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 2,701.00 | 292.00 | 116.14 | 134.47 | 211.13 | 163.66 | 43.70 | 152.70 | 81.11 | 58.58 | 408.43 | 98.76 |
Inventory Days | 2,027.78 | 696.82 | 98.27 | 91.25 | 19.70 | 188.39 | 34.76 | 91.25 | 0.00 | 0.00 | 0.00 | |
Days Payable | 1,013.89 | 1,294.09 | 645.77 | 511.00 | 192.66 | 135.40 | 0.00 | 0.00 | ||||
Cash Conversion Cycle | 2,701.00 | 1,305.89 | -481.14 | -413.03 | -208.62 | -9.30 | 96.68 | 187.47 | 172.36 | 58.58 | 408.43 | 98.76 |
Working Capital Days | 6,278.00 | 839.50 | -165.91 | -259.34 | 797.99 | 137.82 | 706.87 | 975.82 | 910.66 | 13.52 | 11.37 | -77.29 |
ROCE % | -6.78% | -6.27% | -23.91% | -8.76% | 8.49% | 15.54% | 2.44% | 1.06% | 3.16% | -3.23% | 0.34% | -4.98% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - Audited FY25 results with unmodified opinion; new executive director appointed; director changed to non-executive.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report filed; minor 2-day delay in company secretary appointment fined Rs. 2360.
-
Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31.03.2025
30 May - Audited FY25 results with unmodified opinion; appointment of Ankita Mathur as Executive Director; Sushant Mohan Lal becomes Non-Executive Director.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 30.05.2025
30 May - FY25 audited results with loss; new executive director appointed; existing director becomes non-executive.
-
Board Meeting Intimation for Audited Financial Results And Audit Report (Standalone And Consolidated) For The Quarter And Year Ended March 31, 2025 And Any Other Business With The Permission Of The Chair
27 May - Board meeting on May 30, 2025, to approve FY25 audited financial results and audit report.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered:[1][2]
a) Pharmaceuticals: Manufacturing & Marketing of Branded Formulations and Custom Manufacturing for companies. Company also caters to various formulators, manufacturers and Research and Development agencies for their Bulk needs and sources and supplies various drugs and allied products & services to companies upon request.
b) Information Technology: Company has taken over Decipher Software Solutions LLC in USA which is an Information Technology services firm, specializing in ERP Implementation, Mobile & Cloud solutions, Product Development, Offshore Services, Technology Integration and Systems Consulting, Software Development Consulting and Management of IT projects.